EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
CORALVILLE, Iowa, April 05, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Needham & Company’s 15th Annual Healthcare Conference being held in New York, NY, April 12 - 13, 2016.
Details of KemPharm's presentation are as follows:
Date: Tuesday, April 12, 2016
Time: 10:40 AM (ET)
Location: Westin NY Grand Central Hotel; New York, NY
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 [email protected]
